Information Provided By: 
Fly News Breaks for May 11, 2018
CRBP
May 11, 2018 | 15:08 EDT
Cantor Fitzgerald analyst Elemer Piros reiterates an Overweight rating on Corbus Pharmaceuticals with a $32 price target following the company's Q1 results. The analyst views 2018 as a "big year for execution" with the initiation of the Phase 3 RESOLVE-1 study in systemic sclerosis, initiation of the Phase 2b study in cystic fibrosis, and initiation of the Phase 2 study in systemic lupus erythematosus. He finds the stock's current valuation attractive.
News For CRBP From the Last 2 Days
There are no results for your query CRBP
